Prospects for US–Cuba Cooperation in Gastroenterology, Hepatology and Liver Transplantation

Marlen I. Castellanos-Fernández MD PhD, Mirtha Infante-Velázquez MD PhD, Enrique Arús-Soler MD PhD, Marcelo Kugelmas MD FAASLD FACP, Ramón Bataller MD PhD, Ramón Villamil-Martínez MD, Zaily Dorta-Guridi MD PhD, Marlen I. Castellanos-Fernández MD PhD, Mirtha Infante-Velázquez MD PhD, Enrique Arús-Soler MD PhD, Marcelo Kugelmas MD FAASLD FACP, Ramón Bataller MD PhD, Ramón Villamil-Martínez MD, Zaily Dorta-Guridi MD PhD, Caridad Ruenes-Domenech MD MS

ABSTRACT
Gastroenterology, hepatology and liver transplant exchanges between the USA and Cuba have mainly consisted of scientific events and short visits. This has facilitated Cuba’s inclusion in recognized scientific organizations, familiarity with Cuba’s biotech products for treatment of liver disease, and access by Cuban professionals to the highest level of scientific information for clinical practice. It has also given health professionals in the US a more accurate picture of Cuba’s health sector. The results of the Global Alcoholic Liver Disease Survey, which included Cuba and was designed and coordinated in the USA, opened doors to joint research and scientific publications. Until now, there have been no protocols for ongoing cooperation to enable bilateral clinical trials or continuing professional development in diagnostic, therapeutic and surgical techniques for hepatology and liver transplantation. There are many mutually beneficial research prospects in these areas. What has been accomplished to date, described in this article, is encouraging and sets the stage for future collaboration.

KEYWORDS Hepatology, liver transplant, health, medicine, science, Cuba, USA

INTRODUCTION
Chronic liver disease is a serious global health issue. Global deaths due to hepatic cirrhosis increased from some 676,000 in 1980 to >1,000,000 in 2010, and the mortality rate increased by 10.3% between 2005 and 2015. Average prevalence of autopsy-detected hepatic cirrhosis is ≤10%, but this is likely an underestimate, since one third of patients are asymptomatic for many years. The main causes of cirrhosis are alcohol, nonalcoholic fatty liver disease and viral hepatitis, which occur in all countries, regardless of geography or level of economic development. These diseases have enormous health and social costs, including direct health care expenses and indirect costs from productive years of life lost. It is estimated that viral hepatitis causes 53% of hepatic cirrhosis and 54% of liver cancers.[1–3]

In the USA, the burden of chronic liver diseases is substantial and has been increasing. The National Health and Nutrition Examination Survey, conducted between 1999 and 2010, estimated cirrhosis prevalence at 0.27%, or 633,323 adults. Diabetes, alcohol abuse, hepatitis B and C, male sex and old age were independently associated with cirrhosis. The first three factors contributed to 53.5% of cases.[4] Age-adjusted mortality from chronic liver disease and cirrhosis increased from 9.6 per 100,000 in 1999 to 10.2 per 100,000 in 2013 (with more marked increase in the group aged 55–64 years), making it the 12th leading cause of death in 2013 (1.4% of all deaths).[5] Research and interventions to improve patient health are needed.

In Cuba, cirrhosis and chronic liver disease have been the 9th and 10th leading causes of death in the last 20 years; taken together, they have the second highest mortality rate among digestive disease, after colon cancer, and are a major hospital discharge diagnosis.[6] The main causes of chronic hepatitis and cirrhosis in Cuba are the same as in other countries in the Americas Region: viral infections (particularly hepatitis C) and alcohol.[7] Although hepatitis B (HBV) is a leading cause in many countries, it is not in Cuba, where incidence and prevalence of hepatitis B have been decreasing because of a national program to vaccinate at-risk groups and people aged <25 years.[8]

Cuba uses a multidisciplinary and intersectoral approach to finding scientific and technological solutions to resolve, or at least mitigate, the problem of chronic liver disease. The biotech and medical/pharmaceutical industries have been key to providing products and technological resources.[9]

Hepatology, which is relatively new in Cuba, has seen advances in diagnosis, research, and clinical and surgical practice. Various lines of research have resulted from scientific exchange between gastroenterologists and researchers from the former Western Havana Scientific Pole (a group of institutions, now under BioCubaFarma, dedicated to the full research and development cycle aimed at promoting biotechnological development and advanced technologies to resolve health and nutrition problems, while generating revenue for Cuba from competitive products).[10] Joint research beginning in the 1980s led to Cuban production of interferon (in its various forms) for treatment of viral hepatitis B and C, and the hepatitis B vaccine, HeberbiovacHB,[11–13] which helped reduce incidence and prevalence of liver infections.

Other research explores the natural history of hepatic cirrhosis, hepatocellular carcinoma, viral hepatitis, nonalcoholic fatty liver, alcoholic liver disease, autoimmune liver diseases and inherited diseases, and new technologies are being invented to improve their diagnosis.[14–19] Liver transplantation began in Cuba in 1986 but was discontinued in the early 1990s. Since the national liver transplantation program in Cuba was restarted in 1999, >400 liver transplants have been performed, over 80 of them in patients aged <18 years.[20] Although scientific policies are a priority in Cuba and important resources are being invested for

IMPORTANCE Progress in hepatology and liver transplantation has helped Cuba overcome great health challenges. Unique models have been established for future collaborations that will benefit both countries.
Lessons in International Cooperation

At the same time, Cuba shared its advances in biotechnology for treating acute and chronic viral hepatitis C with a Cuban biotech product, recombinant interferon alfa-2b, produced by the Genetic Engineering and Biotechnology Center.[24–26] Results were presented at the First Boston-Cuba Gastroenterology Conference (1999).

The first contact between US and Cuban liver transplantation specialists was facilitated in 2009 by Global Links (a Pittsburgh-based nonprofit organization that provides large-scale humanitarian medical aid) and consisted of a visit by professionals from the pediatric transplant team at William Soler University Children’s Hospital in Havana to an equivalent service in the USA (Table 1).[27]

One important result of these exchanges was the inclusion of Cuba’s Gastroenterology Institute in the Global Alcoholic Liver Disease Survey (GLADIS),[28] which was coordinated by Dr Ramón Bataller (then of the Division of Gastroenterology and Hepatology at University of North Carolina at Chapel Hill). This research, conducted in 2015, explored possible clinical and etiological differences among patients with chronic liver disease. The research involved 3000 patients from 16 gastroenterology and hepatology centers in 23 countries. The study also collected anthropometric, etiologic and clinical data on 100 patients admitted consecutively with early liver disease (not cirrhosis or decompensated disease) seen as outpatients and 100 patients who were hospitalized for liver disease.

To date, activities have been focused on two main categories: short visits by Cuban gastroenterologists to prestigious US institutions, and participation by specialists at conferences held in both countries with joint clinical and endoscopic work (Table 1). The short visits offered the Cubans new knowledge and skills through the expertise of highly qualified professionals in gastroenterology and digestive endoscopy. As part of the exchange, US specialists donated endoscopic equipment and supplies to Cuban services.

Collaboration in gastroenterology, and specifically hepatology, predated renewal of diplomatic relations. It has focused on developing Cuban hepatologists’ and transplantologists’ technical skills in US settings, sharing areas for learning and discussion with US professionals about medical and gastroenterology practice in Cuba, and Cuba’s National Health System (NHS). Exchange began in 1996 with visits by US gastroenterologists from Boston and Portland (ME) to explore Cuban gastroenterologists’ research and their clinical and procedural advances (Table 1), having limited previous knowledge of Cuban medicine and gastroenterology, acquired through visits supported by the US Presbyterian Church.

Table 1: Exchanges between Cuba and the USA since 1996 in gastroenterology, hepatology and liver transplantation

<table>
<thead>
<tr>
<th>Year</th>
<th>Type of activity</th>
<th>Country</th>
<th>Actions/Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1996</td>
<td>US gastroenterologists visit Hermanos Ameijeiras Clinical–Surgical Teaching Hospital</td>
<td>Cuba</td>
<td>Presentation of scientific results Planning of new meetings in both countries for collaboration</td>
</tr>
<tr>
<td>1999</td>
<td>Short placements of Cuban specialists at Lahey Hospital Medical Center and Beth Israel Medical Center</td>
<td>USA</td>
<td>Endoscopies, rounds, joint endoscopic retrograde cholangiopancreatography</td>
</tr>
<tr>
<td>1999</td>
<td>1st Boston–Cuba Gastroenterology Conference</td>
<td>USA</td>
<td>Discussion of scientific results with Cuban biotech products</td>
</tr>
<tr>
<td>2009</td>
<td>Short placements of Cuban hepatologists and transplant specialists at Children’s Hospital of Pittsburgh (University of Pittsburgh Medical Center)</td>
<td>USA</td>
<td>Knowledge about new procedures, treatments, managing intensive therapy, hepatology, anesthesiology, immunology, emergency room and abdominal organ transplants</td>
</tr>
<tr>
<td>2015</td>
<td>Global Alcoholic Liver Disease Survey (GLADIS)</td>
<td>Cuba</td>
<td>Inclusion of Cuba in US-coordinated, international, multicenter research on alcoholic liver disease</td>
</tr>
<tr>
<td>2017</td>
<td>2017 Hepatology Symposium</td>
<td>Cuba</td>
<td>Exchanges on liver transplantation: handling complications, results from living-donor transplants and variants, new immunosuppressive therapies. For liver disease: HBC treatment and results of direct-acting antivirals, management of hepatocellular carcinoma, nonalcoholic fatty liver disease, alcoholic liver disease</td>
</tr>
<tr>
<td>2017</td>
<td>The Liver Meeting</td>
<td>USA</td>
<td>Presentation of experience and impact of Cuba’s HBC prevention and treatment program. Inclusion of Cuba in IC–HEP Council</td>
</tr>
</tbody>
</table>

HBC: hepatitis B and C  IC–HEP: International Coalition of Hepatology Education Providers
Lessons in International Cooperation

The support of organizations dedicated to providing the latest information and facilitating clinical education on liver disease to health professionals was critically important for these exchanges, including the International Coalition of Hepatology Education Providers, the Liver Health Connection and the Chronic Liver Disease Foundation, as well as Cuba’s Gastroenterology Institute and the Cuban Gastroenterology Society.

**ANALYSIS**

Cuba’s NHS guarantees free and universal health care. The system is pyramidal, based on primary care, where family doctor-and-nurse offices and multispecialty polyclinics focus on disease prevention and promotion of health, referring patients to secondary-specialty care when necessary. Tertiary care institutions conduct research and handle more advanced techniques and procedures,[29] including liver transplants.

These characteristics of the Cuban health care system offer excellent opportunities for large-scale collaboration and research projects. Doctors and researchers are well-trained and qualified, supported by a national network of health care facilities with a uniform structure and a consolidated hospital management system that offers diagnostic and therapeutic options under ethical principles established by accredited ethics committees in all institutions. This structure favors obtaining reliable data regarding morbidity and mortality rates for different diseases, as well as other health statistics. Reliable records are kept of all research conducted.[30]

In this context, Cuba offers favorable conditions for clinical trials in patients with chronic liver conditions (such as viral hepatitis, nonalcoholic fatty liver disease and alcoholic liver disease) who have not received specific antiviral treatment or have not responded favorably to antivirals available in Cuba. There have been no clinical trials to date involving both countries. Such trials would be beneficial for assessing direct-acting antivirals for treatment of chronic hepatitis C infection (including patients with end-stage kidney disease) and certain forms of ablative treatment of hepatocellular carcinoma, in which the USA has experience.

The First Boston–Cuba Gastroenterology Conference allowed US specialists to appreciate Cuban advances in gastroenterology and hepatology, with use of Cuban therapeutic biotech products. This led to the first inclusion of Cuban doctors in the American Gastroenterology Association. For their part, Cubans updated their knowledge of technological and scientific developments in gastroenterology and increased clinical and endoscopic skills vital to quality practice.

The 2009 visit by Cuban transplantologists to the pediatric transplant unit in the Children’s Hospital of Pittsburgh (University of Pittsburgh Medical Center) did not lead to changes in medical or surgical protocols in place in Cuban transplantation services since 2004, but did bring about smaller changes in procedures for deep vein thrombosis prophylaxis and pediatric anesthetics. The focus of Cuba’s medical system and its advances in hepatology, hepatobiliary surgery and pediatric transplantation were presented. Another highlight of the experience was the opportunity for Cubans to meet Dr Thomas Earl Starzl, known as the father of modern transplantology, who performed the first liver transplant; his innovations in surgery, immunology and immunosuppression revolutionized the field.[31]

GLADIS showed that referrals of patients with liver disease to specialty care varied significantly by country. Referrals of alcoholic patients occurred in more advanced stages than for patients with viral or nonalcoholic liver disease. Specific patterns were recognized in Cuban patients on diagnosis and referral to specialized services. Patients with autoimmune hepatitis, HBV and HBV+HCV coinfection were diagnosed in early stages, while alcoholic liver disease, alone or associated with HCV, was diagnosed in advanced stages, mostly with complications of hepatic cirrhosis.[28] Early diagnosis of liver disease from HBV infection is associated with Cuba’s viral hepatitis prevention and control program in primary care, which includes actions in surveillance, awareness promotion, vaccination and prevention in general. The program’s impact on controlling hepatitis from HBV has been documented.[32–34] However, despite preventive actions, HCV is still a leading cause of advanced liver disease and liver transplantation in Cuba.[35]

Alcoholism is a mounting challenge in the Americas, which has higher levels of alcoholism, on average, than the rest of the world.[36] According to Cuba’s 2014 Multiple Indicator Cluster Survey, 46.5% of men and 19.2% of women aged 15–49 years report consuming alcohol in the past month.[37]

Inclusive Cuba in GLADIS was a progressive step in addressing alcohol-related liver disease; its results warn of the threat of a disease that starts silently, goes unnoticed, and ends fatally due to complications. Early detection and timely referral to specialized centers are needed for these patients, as part of strategies that can be shared in collaboration between Cuba and the USA.

US specialists participating in the 2017 Hepatology Symposium learned how Cuba’s health care system is organized, and about hepatology and liver transplantation work in Cuba. They also became familiar with progress in biotechnology and pharmaceuticals, closely linked to progress in hepatology, and learned about Cuba’s national health care programs, such as those for viral hepatitis prevention and control, immunizations, HIV/AIDS, and others that connect the NHS with biotechnology institutions This exchange was enriched with an opportunity to visit institutions dedicated to hepatology and liver transplantation in Cuba, such as the Gastroenterology Institute and the Medical–Surgical Research Center.

Cuba’s inclusion for the first time in The Liver Meeting was an opportunity for delegates to highlight Cuba’s experience in and impact on the prevention and treatment of hepatitis B,[35] presenting the current state of hepatitis in Cuba and outlining prospects for future collaboration. These meetings between Cuban and US specialists also facilitated Cuba’s incorporation into the Latin American Association for the Study of the Liver (ALEH) and the International Coalition of Hepatology Education Providers, two leading organizations in the study of liver disease. The Chair of the Cuban Gastroenterology Society attends meetings of ALEH’s Board of Directors.

These exchanges are a good starting point for Cuba’s inclusion in leading scientific organizations, for sharing knowledge of Cuban biotech products for treatment of liver disease, and for Cuba to become a partner in multinational research on liver disease. In this regard, such contacts must be further developed to open
CONCLUSIONS

Progress in hepatology and liver transplantation has helped Cuba overcome great health challenges. The US–Cuba exchange has contributed to new knowledge for both countries. Cuban professionals have gained access to high-level scientific information and clinical practice, while their US colleagues have learned and seen evidence of the development of the health sector in Cuba. This has helped resolve doubts and deepen understanding of Cuba’s reality and prospects for research in this area, sowing the seeds for future collaboration.

ACKNOWLEDGMENTS

The authors thank Yenisley Ortega Betancourt for her valuable contribution to drafting and correcting this manuscript.

REFERENCES


Lessons in International Cooperation
Lessons in International Cooperation


THE AUTHORS
Marlen I. Castellanos-Fernández (Corresponding author: mcastell@infomed.sld.cu), gastroenterologist with a doctorate in medical sciences. Full professor and senior researcher, Teaching and Research Department, National Gastroenterology Institute (ING) and Medical University of Havana (UCMH), Cuba.

Mirtha Infante-Velázquez, gastroenterologist with a doctorate in medical sciences. Full professor and senior researcher, Teaching and Research Department, ING and UCMH, Havana, Cuba.

Enrique Ánus-Soler, gastroenterologist with a doctorate in medical sciences. Full professor and senior researcher and consultant, ING and UCMH, Havana, Cuba.

Marcelo Kugelmas, gastroenterologist. Director, hepatology and research, South Denver Gastroenterology, Denver, USA; clinical associate professor, University of Colorado, Aurora, USA.

Ramón Bataller, gastroenterologist and hepatologist. Professor, University of Pittsburgh, Pittsburgh, USA.

Ramón Villamil-Martínez, physician with dual specialties in family medicine and pediatric surgery. Head of pediatric liver transplantation, William Soler University Children’s Hospital and UCMH, Havana, Cuba.

Zaily Dorta-Guridi, gastroenterologist with a doctorate in medical sciences. Full professor and associate researcher in hepatology, ING and UCMH, Havana, Cuba.

Caridad Ruenes-Domech, gastroenterologist with a master’s degree in higher medical education. Associate professor and Director, ING and UCMH, Havana, Cuba.

International Congress:
Controlling Diabetes and its More Severe Complications
Plaza América Convention Center, Varadero, Cuba
December 10–14, 2018
Main topics:

- Diabetes prevention
- Diabetes as metabolic syndrome
- Obesity and diabetes
- Diabetes types 1 and 2: global medical updates in early detection, metabolic control and treatment
- Gestational diabetes
- Comprehensive care of diabetes in pregnancy
- Growth factors and wound healing
- Diabetic foot ulcer
- Postmarketing pharmacosurveillance of Heberprot-P in Cuba